DKSH Holding has entered into a distribution and promotion agreement with Eli Lilly and Co. to sell, promote and distribute Lilly's pharmaceutical products in Hong Kong and Macau. The financial terms were not disclosed. The deal expands the companies' existing collaboration in Singapore and Vietnam, giving DKSH the rights to commercialize Lilly's current pharmaceutical portfolio in the two markets. DKSH said the partnership will leverage its commercial, medical affairs and distribution capabilities to support patient access to Lilly's medicines, with patient support programs and engagement with healthcare professionals continuing under the arrangement.
DKSH Holding AGDKSH secures rights to commercialize Lilly's pharmaceutical portfolio in Hong Kong and Macau, expanding its business and revenue stream.
Eli Lilly and CompanyEli Lilly gains expanded distribution in Hong Kong and Macau through DKSH, potentially increasing sales of its pharmaceutical products.